We observed similar levels of anti-MBP and anti-MOG antibody content in B cells in the MS-naïve patient group (16.41 ± 5.00 ng/mL and 13.59 ± 9.74 ng/mL, respectively) compared with the MS-treated group (15.68 ± 8.43 ng/mL and 15.64 ± 15.36 ng/mL, respectively) (p=0.62 and p=0.56, respectively). Here, MBP is linked to myeloid sarcoma.